ReviewPostepy dermatologii i alergologii2026
Efficacy and safety of PDE4 inhibitor monotherapy in adult patients with atopic dermatitis: a systematic review and meta-analysis.
Review in Postepy dermatologii i alergologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory disease. Phosphodiesterase-4 (PDE4) inhibitors have emerged as a potential therapeutic strategy, but their efficacy and safety profile in adult patients requires comprehensive evaluation. Aim: To assess the efficacy and safety of PDE4 inhibitor monotherapy in adult AD patients. Methods: A systematic literature search was conducted for studies evaluating PDE4 inhibitor monotherapy in adult AD patients. Study quality was assessed using the Newcastle-Ottawa Scale, and statistical analyses were performed using Review Manager 5.3. Results: Five studies were included. Topical PDE4 inhibitors significantly reduced EASI scores within 4 weeks, with MD = -3.77 [-6.92, -0.62] ( Conclusions: PDE4 inhibitor monotherapy provides clinically meaningful treatment for adult atopic dermatitis patients. Topical formulations demonstrate rapid symptomatic improvement and favourable tolerance. Oral administration exhibits cumulative efficacy for severe disease but requires careful risk-benefit assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.